Philip Watt CEO, of Cystic Fibrosis Ireland says "CF patients in Ireland are dismayed by today’s ruling from the NCPE which recommends that ground breaking drug ‘Orkambi’ is not funded".
However CFI notes that the NCPE ruling states that Orkambi is not funded ‘at submitted cost’ and this opens the door to further price negotiations.
Cystic Fibrosis Ireland calls on the Government to clarify if it will enter into further negotiations and calls on the pharma company Vertex to significantly reduce the price of Orkambi as part of these negotiations.
Cystic Fibrosis Ireland welcomes the fact that the positive health impact of Orkambi is recognised by the NCPE in today’s judgement.
Philip Watt CEO of Cystic Fibrosis Ireland states "we support a fairer deal for this drug but it will be a travesty if this drug is not provided to our patients or if there is a significant delay in providing this drug".
Note: Around 500 people with CF have the potential to benefit from Orkambi in Ireland.
For press enquiries please contact Philip Watt on 087-6370557.